|
|
|
The foregoing release contains forward-looking statements that can be identified by terminology such as "expected," "will," "can," "dedicated," "potential," or similar expressions, or by express or implied discussions regarding potential marketing approvals for Menveo or regarding potential future revenues from Menveo. In 2008, the Group's continuing operations achieved net sales of USD 41. For more information, please visit www. The six month study, led by Zeljko Vujaskovic, M. The remaining animals that received AEOL 10150 did not need to be sacrificed based on animal care rules, but a majority were sacrificed in order to increase the numbers that could be compared to the untreated animals sacrificed at 45 days, since there would be no untreated animals for comparison at the end of six months. A number of treated animals continued to be monitored until the end of six months and analysis of those animals is currently underway. Twenty animals received a 40 mg loading dose of AEOL 10150 two hours after exposure and then received 20 mg of AEOL 10150 three times per week for four weeks. In previous studies it has been shown that doses in the range of 5 to 30 mg/kg AEOL 10150 given daily starting up to 24 hrs after irradiation and administered for as long as 10 weeks mitigate functional lung injury in Fischer 344 rats.
-- Multiple Applications – AEOL 10150 has demonstrated protective effects against radiation and mustard gas exposure, and within these indications has shown the ability to treat multiple organ systems. Additionally, based on its mechanism, it is believed that the compound may potentially protect against exposure to chlorine gas.
valium xanax ambien zolpidem ambien hydrocodone xanax cheap 2mg xanax overnight kava xanax side effects picture of the pill xanax xanax alprazolam overnight delivery xanax side effects paranoia xanax suicide xanax valium quick
Novartis Vaccines is a global leader in providing vaccines to protect against deadly meningococcal disease. In addition to Menveo, Novartis Vaccines is developing a recombinant vaccine for its potential to provide broad coverage against multiple strains of serogroup B, for which no vaccine is currently available. Serogroups B and C are predominant in Europe. Novartis is the only company with leading positions in these areas.--(BUSINESS WIRE)--Jul 6, 2009 - Aeolus Pharmaceuticals, Inc.D. These results have also been used to design a proof of principle study in non-human primates, which is expected to begin within the next thirty days.
|
|
No News has been posted yet
|
|
|
Forgotten your password? Request a new one here.
|
 Guests Online: 1
No Members Online
Registered Members: 1
Unactivated Members: 0
Newest Member: Owen Electrical
|
|
v6.01.1 © 2003-2005